Clinical trials: Chidamide, active
Cutaneous T-cell Lymphoma (CTCL)
Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma.
- Trial name
- NCT07754890
- Testing
- golidocitinib, Chidamide
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
APL
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment.
- Trial name
- NCT05881265
- Testing
- Chidamide+venetoclax
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Adult, Newly Diagnosed
Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia
This prospective, multi-center, randomized, controlled Phase II study is to compare the therapeutic efficacy and side effect of VACl (Venetoclax,Azacitidine,Cladribine) alternating with VACh (Venetoclax,Azacitidine,Chidamide)…
- Trial name
- NCT06532552
- Testing
- VACl, VACh, VACl Alternating With VACh
- Where
- China
- Volunteers
- 172 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Double Expressor DLBCL
Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL
This is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with…
- Trial name
- NCT07415980
- Testing
- Polatuzumab Vedotin, Rituximab (R), Chidamide
- Volunteers
- 68 people
- Sponsor
- Sun Yat-sen University
Diffuse Large B-Cell Lymphoma
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL)…
- Trial name
- DEL-MRD-CHID (NCT07507318)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Rong Tao
Newly Diagnosed Peripheral T-cell Lymphoma
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.
- Trial name
- NCT05976997
- Testing
- Duvelisib, Chidamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Liling Zhang
Pancreatic Cancer, Adult
Adebrelimab and Chidamide for Pancreatic Cancer
Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is…
- Trial name
- ACPC (NCT06584227)
- Testing
- Adebrelimab and Chidamide Combined with Gemcitabine and S1
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liu Xiufeng
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
This study aims to compare the efficacy and safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/PD1 (Pola-RCHP-X) versus RCHOP-X…
- Trial name
- NCT06516978
- Testing
- Polatuzumab vedotin, Rituximab, Cyclophosphamide
- Volunteers
- 528 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor
Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.
This study is a prospective, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of PD-1 inhibitor combined with tenofovir, chidamide, and lenalidomide in the treatment of relapsed or refractory…
- Conditions
- EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133763
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.
- Volunteers
- 50 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Acute Monocytic Leukemia, Newly Diagnosed
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy
- Trial name
- NCT05566054
- Testing
- Chidamide, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 92 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Extranodal Natural Killer T Cell Lymphoma
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of chidamide, anti-PD1 antibody, and pegaspargase versus dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP) in…
- Trial name
- NCT06255795
- Testing
- chidamide, anti-PD1 antibody, and pegaspargase, DDGP
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer
Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced…
- Trial name
- NCT06858956
- Testing
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Leukemia, Myeloid, Acute, Relapsed Adult AML
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
- Conditions
- Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
- Trial name
- NCT05305859
- Testing
- venetoclax combining chidamide and azacitidine (VCA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
DLBCL
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
This is a prospective, observational, multicenter, cohort study with 400 newly treated DLBCL patients. To evaluate the clinical efficacy and safety of tucidinostat in the real-world treatment of primary diffuse large B-cell…
- Trial name
- NCT06779435
- Testing
- Low intensity treatment options, Conventional immunochemotherapy regimen
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Ruijin Hospital
Peripheral T Cell Lymphoma
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or chidamide in the treatment of relapsed or…
- Trial name
- NCT07093710
- Testing
- Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Sun Yat-sen University
Double Expressor DLBCL, ELDERLY PEOPLE
Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL
To evaluate the efficacy and safety of Chidamide in combination with lenalidomide and rituximab (CR2) as induction therapy, followed by chidamide maintenance in responding patients with newly diagnosed elderly/unfit…
- Conditions
- Double Expressor DLBCL, ELDERLY PEOPLE, Unfit, New-diagnosis DLBCL
- Trial name
- CR2 (NCT07884708)
- Testing
- Chidamide in combination with Lenalidomide and Rituximab (CR2)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-Small Cell Lung Cancer
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of Chidamide in combination with Ivonescimab in the treatment of advanced non-small cell lung cancer with secondary…
- Trial name
- NSCLC， YAP (NCT07412262)
- Testing
- Chidamide in combination with Ivonescimab
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Guangdong Association of Clinical Trials
Peripheral T Cell Lymphoma
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
This is a randomized, open-label, active controlled, multi-center, phase 3 clinical study to compare the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with Chidamide in patients with relapsed/refractory…
- Trial name
- NCT04668690
- Testing
- Mitoxantrone Hydrochloride Liposome Injection, Chidamide
- Where
- China
- Volunteers
- 193 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Peripheral T-Cell Lymphoma, Not Classified
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population.
- Trial name
- NCT07081607
- Testing
- golidocitinib with azacytidine and chidamide
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer Metastatic
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced…
- Trial name
- NCT06682247
- Testing
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
- Volunteers
- 200 people
- Sponsor
- Feng Wang